Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.67 |
| ▸ | CA1 | P00915 | 2/20 | 0.67 |
| ▸ | CA2 | P00918 | 2/20 | 0.67 |
| ▸ | CA4 | P22748 | 2/20 | 0.67 |
| ▸ | CA6 | P23280 | 2/20 | 0.67 |
| ▸ | CA7 | P43166 | 2/20 | 0.67 |
| ▸ | CA9 | Q16790 | 2/20 | 0.67 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.67 |
| ▸ | CA3 | P07451 | 1/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.67 |
| ▸ | CA5A | P35218 | 1/20 | 0.67 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.67 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.62 |
| ▸ | TPMT | P51580 | 3/20 | 0.59 |
| ▸ | HTT | P42858 | 3/20 | 0.55 |
| ▸ | CNR2 | P34972 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | LCK | P06239 | 1/20 | 0.52 |
| ▸ | FYN | P06241 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21821412 | 0.88 | CA12 (0.58) | CA12CA1CA2CA4CA6 | |
| SCHEMBL15197099 | 0.88 | CA12 (0.58) | CA12CA1CA2CA4CA6 | |
| SCHEMBL30808277 | 0.88 | CA12 (0.58) | CA12CA1CA2CA4CA6 | |
| SCHEMBL20742895 | 0.87 | CA12 (0.56) | CA12CA1CA2CA4CA6 | |
| SCHEMBL18340205 | 0.87 | HTT (0.59) | CA12CA1CA2CA4CA6 | |
| SCHEMBL2389998 | 0.83 | LMNA (0.67) | CA12CA1CA2CA4CA6 | |
| SCHEMBL15476001 | 0.81 | RXRA (0.61) | KMT2ARAB9A | |
| SCHEMBL731344 | 0.81 | MAPT (0.53) | CA12CA1CA2CA4CA6 | |
| SCHEMBL985988 | 0.81 | TSHR (0.44) | CA12CA1CA2CA4CA6 | |
| SCHEMBL1612307 | 0.81 | TSHR (0.68) | CA12CA1CA2CA4CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118184679-A | Photothermal agent and preparation method thereof, photothermal nanoparticle and preparation method thereof, insulating material and self-repairing method of insulating material | 中国石油天然气股份有限公司 | 2024-06-14 | — | — | CN | claimed |
| CN-112321416-A | Method for synthesizing bromocriptine intermediate 4-bromo-3, 5-dimethoxybenzoic acid | 李小军 | 2021-02-05 | — | — | CN | claimed |
| CN-1746144-A | Preparation of 4-bromine-3,5-dimethoxybenzoic alcohol | LUZHOU PHARMACEUTICAL CO LTD D (CN) | 2006-03-15 | — | — | CN | claimed |
| CN-122029153-A | Aromatic hydrocarbon receptor modulator compound, and preparation method and application thereof | 德明药泰生物技术（深圳）有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20250381168-A1 | VLA4 INHIBITORS AND USES THEREOF | WASHINGTON UNIVERSITY ST LOUIS (US) | 2025-12-18 | — | — | US | disclosed |
| US-12435066-B2 | Substituted tricyclic compounds | LUPIN LIMITED (IN) | 2025-10-07 | — | — | US | disclosed |
| WO-2025136811-A1 | CHEMICAL COMPOUNDS AND USES THEREOF | IDEAYA BIOSCIENCES, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-12338203-B2 | Urea compound for antagonizing LPA1 receptor | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2025-06-24 | — | — | US | disclosed |
| WO-2025092989-A1 | SUBSTITUTED QUINAZOLINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMBINATION THEREOF, AND USE THEREOF | 泰州红云制药有限公司 | 2025-05-08 | — | — | WO | disclosed |
| WO-2025082312-A1 | AROMATIC HYDROCARBON RECEPTOR MODULATOR COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 德明药泰生物技术（深圳）有限公司 | 2025-04-24 | — | — | WO | disclosed |
| CN-119823001-A | Urea compounds antagonizing LPA1 receptor | 大正制药株式会社 | 2025-04-15 | — | — | CN | disclosed |
| EP-1403250-A1 | BIS(5-ARYL-2-PYRIDYL) DERIVATIVE | Kowa Co., Ltd. (JP) | 2004-03-31 | — | — | EP | disclosed |
| US-6706703-B2 | BIS(5-ARYL-2-PYRIDYL) COMPOUND HAVING EXCELLENT IMMUNOGLOBULIN (IGE) ANTIBODY PRODUCTION INHIBITING ACTIVITY, USEFUL FOR THE PREVENTION OR TREATMENT OF ALLERGIC IMMUNE DISEASES | KOWA CO., LTD. (JP) | 2004-03-16 | — | — | US | disclosed |
| WO-2003104213-A1 | PREPARATION PROCESS OF BIPHENYLCARBOXYLIC ACID AMIDE DERIVATIVES | KOWA CO., LTD. (JP) | 2003-12-18 | — | — | WO | disclosed |
| US-20030232992-A1 | Preparation process of biphenylcarboxylic acid amide derivatives | KOWA CO., LTD. (JP) | 2003-12-18 | — | — | US | disclosed |
| US-20030027814-A1 | Bis(5-aryl-2-pyridyl) derivatives | KOWA CO., LTD. (JP) | 2003-02-06 | — | — | US | disclosed |
| EP-0687249-A1 | BALANOIDS | ELI LILLY AND COMPANY (US) | 1995-12-20 | — | — | EP | disclosed |
| WO-1994020062-A2 | BALANOIDS AS PROTEIN KINASE C INHIBITORS | ELI LILLY AND COMPANY (US) | 1994-09-15 | — | — | WO | disclosed |
| US-4076810-A | Benzylpyrimidine antibacterial composition | HOFFMANN-LA ROCHE INC. (US) | 1978-02-28 | — | — | US | disclosed |
| US-4024145-A | Benzylpyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 1977-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12338203-B2 | Urea compound for antagonizing LPA1 receptor | LPAR1, LPAR2, LPAR3 | CA12 4211/4885CA1 3476/4885CA2 2098/4885 |
| US-20030027814-A1 | Bis(5-aryl-2-pyridyl) derivatives | AHR, PAH, H1-0 | CA12 4529/4885CA1 4598/4885CA2 2662/4885 |
| US-20030232992-A1 | Preparation process of biphenylcarboxylic acid amide derivatives | CD22, C9, FCGR1A | CA12 157/4885CA1 37/4885CA2 42/4885 |
| US-12435066-B2 | Substituted tricyclic compounds | SOS1, RSU1, KSR1 | CA12 3964/4885CA1 2843/4885CA2 1678/4885 |
| US-20250381168-A1 | VLA4 INHIBITORS AND USES THEREOF | CXCR4, SDF4, ITGB4 | CA12 2667/4885CA1 3154/4885CA2 4405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.